Search Results - "Palluzzi, Eleonora"

Optimizing treatment in recurrent epithelial ovarian cancer by Corrado, Giacomo, Salutari, Vanda, Palluzzi, Eleonora, Distefano, Maria Grazia, Scambia, Giovanni, Ferrandina, Gabriella

“…Introduction: Optimal management of recurrent ovarian cancer (ROC) remains an area of uncertainty. An estimated 85% of patients with epithelial ovarian cancer…”
Get full text

Neo-adjuvant platinum-based chemotherapy followed by chemoradiation and radical surgery in locally advanced cervical cancer (Lacc) patients: A phase II study by Ferrandina, Gabriella, Palluzzi, Eleonora, Gallotta, Valerio, Gambacorta, Maria Antonietta, Autorino, Rosa, Turco, Luigi Carlo, Macchia, Gabriella, Cosentino, Francesco, Gui, Benedetta, Mattoli, Maria Vittoria, Ronzino, Graziana, Valentini, Vincenzo, Scambia, Giovanni

“…The aim of this Phase II, non-randomized study was to assess activity and safety of neoadjuvant chemotherapy (NACT) before chemoradiation (CT/RT) followed by…”
Get full text

Dose-dense paclitaxel/carboplatin as neo-adjuvant chemotherapy followed by radical surgery in locally advanced cervical cancer: a prospective phase II study by Ferrandina, Gabriella, Corrado, Giacomo, Vitrano, Giuseppe, Gallotta, Valerio, Palluzzi, Eleonora, Distefano, Mariagrazia, Scambia, Giovanni

“…Purpose The role of dose-dense schedules in the neo-adjuvant treatment (NACT) of locally advanced cervical cancer (LACC) has been reported. This phase II study…”
Get full text

Endometriosis-associated clear cell carcinoma arising in caesarean section scar: a case report and review of the literature by Ferrandina, Gabriella, Palluzzi, Eleonora, Fanfani, Francesco, Gentileschi, Stefano, Valentini, Anna Lia, Mattoli, Maria Vittoria, Pennacchia, Ilaria, Scambia, Giovanni, Zannoni, Gianfranco

“…Malignant transformation has been reported in approximately 1% of the endometriosis cases; herein, we report a case of clear cell endometrial carcinoma arising…”
Get full text

Stereotactic Body Radiation Therapy for Oligoprogressive Ovarian Cancer Patients Treated During Poly(ADP‐Ribose)‐Polymerase Inhibitor Maintenance: Efficacy and Adverse Events From the Epimetheo Retrospective Study by Macchia, Gabriella, Pezzulla, Donato, Campitelli, Maura, Russo, Donatella, Ronzino, Graziana, Lucci, Simona, Salutari, Vanda, Di Stefano, Aida, Balcet, Vittoria, Epifani, Valeria, Perrucci, Elisabetta, Marchetti, Claudia, Distefano, Maria Grazia, Palluzzi, Eleonora, Autorino, Rosa, De Luca, Viola, Giannini, Roberta, Rinaldi, Raffaella, Russo, Silvio Andrea, Cilla, Savino, Fagotti, Anna, Gambacorta, Maria Antonietta, Scambia, Giovanni, Deodato, Francesco, Ferrandina, Gabriella

“…The aim of this observational, retrospective, multicenter study (Epimetheo) was to analyze the activity and the safety of stereotactic body radiation therapy…”
Get full text

Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group by Musacchio, Lucia, Palluzzi, Eleonora, Di Napoli, Marilena, Lauria, Rossella, Ferrandina, Gabriella, Angioli, Roberto, Bergamini, Alice, Corrado, Giacomo, Perniola, Giorgia, Cassani, Chiara, Savarese, Antonella, Gori, Stefania, Greco, Filippo, De Angelis, Carmine, Zafarana, Elena, Giannarelli, Diana, Cinieri, Saverio, Mosconi, Anna Maria, Raspagliesi, Francesco, Pignata, Sandro, Scambia, Giovanni, Lorusso, Domenica

“…PARP (poly adenosine diphosphate [ADP]–ribose polymerase) inhibitors are approved as maintenance therapy in platinum sensitive ovarian cancer (OC), in first…”
Get full text

Pathologic response to neoadjuvant chemotherapy in advanced ovarian cancer: utility of a scoring system to predict outcomes by Nero, Camilla, Fagotti, Anna, Zannoni, Gian Franco, Palluzzi, Eleonora, Scambia, Giovanni, Petrillo, Marco

“…Growing evidence supports the role of neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer. Currently, there is no shared…”
Get more information

Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer by Colombo, Nicoletta, Zaccarelli, Eleonora, Baldoni, Alessandra, Frezzini, Simona, Scambia, Giovanni, Palluzzi, Eleonora, Tognon, Germana, Lissoni, Andrea A., Rubino, Daniela, Ferrero, Annamaria, Farina, Gabriella, Negri, Emanuele, Pesenti Gritti, Angela, Galli, Francesca, Biagioli, Elena, Rulli, Eliana, Poli, Davide, Gerardi, Chiara, Torri, Valter, Fossati, Roldano, D‘Incalci, Maurizio

“…Background Trabectedin, in addition to its antiproliferative effect, can modify the tumour microenvironment and this could be synergistic with bevacizumab. The…”
Get full text

Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know? by Boccia, Serena Maria, Sassu, Carolina Maria, Ergasti, Raffaella, Vertechy, Laura, Apostol, Adriana Ionelia, Palluzzi, Eleonora, Fagotti, Anna, Scambia, Giovanni, Marchetti, Claudia

“…In the era of single and combination maintenance therapies as well as platinum and Poly (ADP-ribose) polymerase inhibitors (PARPi) resistance, the choice of…”
Get full text

Real-World Management of Trabectedin/Pegylated Liposomal Doxorubicin in Platinum-Sensitive Recurrent Ovarian Cancer Patients: A National Survey by Ferrandina, Gabriella, Amadio, Giulia, Paris, Ida, Distefano, Mariagrazia, Palluzzi, Eleonora, de Vincenzo, Rosa, Ricci, Caterina, Scambia, Giovanni

“…Trabectedin (T) plus pegylated liposomal doxorubicin (PLD) is approved for treatment of platinum-sensitive recurrent ovarian cancer (ROC). Despite the…”
Get more information

STEREOTACTIC BODY RADIOTHERAPY FOR OLIGOPROGRESSIVE OVARIAN CANCER PATIENTS TREATED DURING PARP INHIBITOR MAINTENANCE: EFFICACY AND ADVERSE EVENTS FROM THE EPIMETHEO RETROSPECTIVE STUDY by Gabriella, Macchia, Donato, Pezzulla, Maura, Campitelli, Donatella, Russo, Graziana, Ronzino, Simona, Lucci, Vanda, Salutari, Aida, Di Stefano, Vittoria, Balcet, Valeria, Epifani, Elisabetta, Perrucci, Claudia, Marchetti, Grazia, Distefano Maria, Eleonora, Palluzzi, Rosa, Autorino, Viola, De Luca, Roberta, Giannini, Raffaella, Rinaldi, Andrea, Russo Silvio, Savino, Cilla, Anna, Fagotti, Antonietta, Gambacorta Maria, Giovanni, Scambia, Francesco, Deodato, Gabriella, Ferrandina

“…The aim of this observational, retrospective, multicenter study (Epimetheo) was to analyze the activity and the safety of SBRT during PARP inhibitors (PARPi)…”
Get full text

Management of BRCA mutation carriers by Paris, Ida, Di Giorgio, Danilo, Palluzzi, Eleonora, Garganese, Giorgia, Terribile, Daniela Andreina, Fragomeni, Simona Maria, D’Archi, Sabatino, Scambia, Giovanni, Masetti, Riccardo

Get full text

Early detection of recurrence or progression disease in patients with ovarian cancer after primary debulking surgery. Correlation between CT findings and CA 125 levels by Giuliani, Michela, Gui, Benedetta, Valentini, Anna L, DI Giovanni, Silvia E, Miccò, Maura, Rodolfino, Elena, Falcione, Matteo, DE Waure, Chiara, Palluzzi, Eleonora, Salutari, Vanda, Scambia, Giovanni, Manfredi, Riccardo

“…There are no standard approaches for follow up in advanced ovarian cancer (AOC) patients; the aim of this study is to evaluate correlation between computed…”
Get more information

Modulation of GemOx chemotherapy according to CIRS in elderly patients with advanced pancreatic cancer by TUDINI, Marianna, PALLUZZI, Eleonora, CANNITA, Katia, MANCINI, Maria, SANTOMAGGIO, Alessandra, BRUERA, Gemma, LANFIUTI BALDI, Paola, PELLICCIONE, Michela, RICEVUTO, Enrico, FICORELLA, Corrado

“…The present study evaluated activity and toxicity of modulated doses of gemcitabine associated to oxaliplatin in patients with secondary CIRS and with locally…”
Get full text